9 completed, 7 recruiting, 4 withdrawn, 2 active not recruiting. 13 Phase 2, 9 Phase 1, 4 Phase 3, 1 Not applicable.
Follow Dystrophic Epidermolysis Bullosa: new trials by email Literature Review of Dystrophic Epidermolysis Bullosa trials Research Report on Dystrophic Epidermolysis Bullosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa ENERGI-F703EB Cream, Matched vehicle cream - Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa | Phase 2 | Recruiting | Energenesis Biomedical Co., Ltd. | 24 | 2026-10-08 | 2026-10-05 |
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) Efgartigimod - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Not yet recruiting | M. Peter Marinkovich | 18 | 2026-07-01 | 2026-05-05 |
| A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study TCP-25 gel, Vehicle (placebo) - Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa | Phase 2 | Recruiting | Xinnate AB | 32 | 2026-01-30 | 2026-10-22 |
| Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa Immunoglobulin G - Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Recruiting | M. Peter Marinkovich | 8 | 2025-08-04 | 2026-05-05 |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa KB803, Placebo - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Recruiting | Krystal Biotech, Inc. | 16 | 2025-06-20 | 2026-03-12 |
| Evaluation of D-Fi for the Treatment of Wounds Due to DEB D-Fi - Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Castle Creek Biosciences, LLC. | 32 | 2025-03-27 | 2026-03-13 |
| MSC EVs in Dystrophic Epidermolysis Bullosa AGLE-102 - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | Aegle Therapeutics | 8 | 2024-08-13 | 2025-06-25 |
| Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops) - Junctional Epidermolysis Bullosa, Epidermolysis Bullosa (EB) | Phase 1 | Active not recruiting | Fundación DEBRA Chile, Niños Piel de Cristal | 20 | 2024-05-07 | 2025-12-31 |
| Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa Ev.FV 1.0 x 1011 par/ml - Dystrophic Epidermolysis Bullosa, Wound Heal | Phase 1 / Phase 2 | Recruiting | Isfahan University of Medical Sciences | 20 | 2024-01-09 | 2025-11-17 |
| Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa ALLO-ASC-SHEET, Vehicle Control - Dystrophic Epidermolysis Bullosa | Phase 2 | Unknown | Anterogen Co., Ltd. | 6 | 2023-05-01 | 2024-04-22 |
| Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene PTW-002 10 mg/g gel, Placebo - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | Phoenicis Therapeutics | 8 | 2023-04-30 | 2023-03-31 |
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Open Label Topical Beremagene Geperpavec (B-VEC) - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 47 | 2021-05-25 | 2024-04-09 |
| Long-Term Follow-up Protocol Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Recruiting | Krystal Biotech, Inc. | 50 | 2021-05-25 | 2021-06-08 | |
| Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD) Decriptive study of EDB - Dystrophic Epidermolysis Bullosa | Completed | Centre Hospitalier Universitaire de Nice | 27 | 2021-01-01 | 2025-04-03 | |
| Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Topical Beremagene Geperpavec, Placebo - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 31 | 2020-08-17 | 2023-02-17 |
| The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Withdrawn | Krystal Biotech, Inc. | 2020-01-01 | 2021-09-17 | ||
| Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa RGN-137, Placebo - Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa | Phase 2 | Terminated | Lenus Therapeutics, LLC | 4 | 2019-05-22 | 2022-08-22 |
| To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) Diacerein 1% Ointment - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex | Phase 1 | Completed | Castle Creek Pharmaceuticals, LLC | 11 | 2018-05-18 | 2020-02-10 |
| A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients Topical beremagene geperpavec, Placebo gel - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Completed | Krystal Biotech, Inc. | 12 | 2018-05-06 | 2023-01-31 |
| A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial ALLO-ASC-DFU - Dystrophic Epidermolysis Bullosa | Completed | Anterogen Co., Ltd. | 2 | 2017-12-08 | 2023-08-25 |
Showing 20 of 26. Sign in to see all of them.
Epidermolysis Bullosa Dystrophica (26) · Epidermolysis Bullosa (11) · Epidermolysis Bullosa, Junctional (5) · Corneal Injuries (2) · Epidermolysis Bullosa Acquisita (2) · Epidermolysis Bullosa Simplex (2)
Collagen Diseases (26) · Congenital Abnormalities (26) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Connective Tissue Diseases (26) · Genetic Diseases, Inborn (26) · Skin Abnormalities (26) · Skin Diseases (26) · Skin Diseases, Genetic (26) · Skin Diseases, Vesiculobullous (26) · Skin and Connective Tissue Diseases (26) · Epidermolysis Bullosa (15) · Corneal Diseases (2) · Craniocerebral Trauma (2) · Eye Diseases (2) · Eye Injuries (2)
Gels (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Ointments (1) · Photochemotherapy (1) · diacerein (1) · efgartigimod alfa (1)
Krystal Biotech, Inc. (6) · Anterogen Co., Ltd. (3) · Centre Hospitalier Universitaire de Nice (2) · M. Peter Marinkovich (2) · Aegle Therapeutics (1) · Castle Creek Biosciences, LLC. (1) · Castle Creek Pharmaceuticals, LLC (1) · Energenesis Biomedical Co., Ltd. (1) · Fundación DEBRA Chile, Niños Piel de Cristal (1) · Healthpoint (1) · Isfahan University of Medical Sciences (1) · Lenus Therapeutics, LLC (1) · Lotus Tissue Repair, Inc. (1) · Phoenicis Therapeutics (1) · Shire (1)
United States (18) · France (4) · Italy (2) · South Korea (2) · Australia (1) · Austria (1) · Chile (1) · Czechia (1) · Germany (1) · Greece (1) · Iran (1) · Poland (1) · Spain (1) · Sweden (1) · Taiwan (1)
Hal Landy, MD (2) · Matt P Marinkovich, MD (2) · David Chien, MD (1) · David T Woodley, MD (1) · Haydar Frangoul, MD (1) · Herbert B Slade, MD (1) · Jaime E Dickerson, PhD (1) · Mary Spellman (1) · Masoud Soleimani, Prof (1) · Su Chan Kim, PhD (1) · Su Chan Kim, PhD. (1)